The UK’s largest pharmaceutical company, AstraZeneca has made its first profit from the sale of its Covid-19 vaccine as the company sold a total of $1.05 billion, contributing one cent to earnings per share.
The company and its sub-licensing partners had released more than 1.5 billion vaccine doses as at 30th September for supply in over 170 countries across the world.
The company now expects to progressively transition to modest profitability as it receives new orders.
The company expressed further that its expected profit contribution in the fourth quarter would offset costs incurred from a Covid-19 antibody combination drug it is presently working on.
